1207 HETEROLOGOUS T CELLS CAN HELP RESTORE FUNCTION IN DYSFUNCTIONAL HEPATITIS C VIRUS SPECIFIC T CELLS DURING THERAPEUTIC VACCINATION
2011; Elsevier BV; Volume: 54; Linguagem: Inglês
10.1016/s0168-8278(11)61209-9
ISSN1600-0641
AutoresLars Frelin, Gustaf Ahlén, A. Chen, Erwin Daniel Brenndörfer, Anette Braß, Fredrik Holmström, M. Chen, Jonas Söderholm, D.R. Milich, Matti Sällberg,
Tópico(s)Hepatitis B Virus Studies
ResumoPOSTERSreceiving ABT-267 and 2/14 (14%) receiving placebo thus, similar rates across groups.Only one AE was considered by the investigator to be study drug-related Conclusions: Based on the observed pharmacokinetics and in vitro replicon activity, ABT-267 doses of 5 mg are predicted to have significant antiviral activity.In healthy subjects, steady-state trough concentrations for a 5 mg dose were approximately 10-fold above the in vitro replicon EC 50 .No safety signals have been identified.These findings support continued development of ABT-267 as a potential once daily NS5A inhibitor.
Referência(s)